Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 9/2017

01-09-2017 | Gynecologic Cancers (NS Reed, Section Editor)

Pathology of Neuroendocrine Tumours of the Female Genital Tract

Authors: Brooke E. Howitt, Paul Kelly, W. Glenn McCluggage

Published in: Current Oncology Reports | Issue 9/2017

Login to get access

Abstract

Neuroendocrine tumours are uncommon or rare at all sites in the female genital tract. The 2014 World Health Organisation (WHO) Classification of neuroendocrine tumours of the endometrium, cervix, vagina and vulva has been updated with adoption of the terms low-grade neuroendocrine tumour and high-grade neuroendocrine carcinoma. In the endometrium and cervix, high-grade neoplasms are much more prevalent than low-grade and are more common in the cervix than the corpus. In the ovary, low-grade tumours are more common than high-grade carcinomas and the term carcinoid tumour is still used in WHO 2014. The term ovarian small-cell carcinoma of pulmonary type is included in WHO 2014 for a tumour which in other organs is termed high small-cell neuroendocrine carcinoma. Neuroendocrine tumours at various sites within the female genital tract often occur in association with other neoplasms and more uncommonly in pure form.
Literature
1.
Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO classification of tumours of the female reproductive organs. Lyon: IARC press; 2014.
2.
Tavassoli FA. Devilee P, eds. Lyon: World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the Breast and Female Genital Organs IARC Press; 2003.
3.
Oberndorfer S. Karzinoide Tumoren des Dunndarms. Frankf Z Pathol. 1907;1:425–32.
4.
5.
Aaltonen LH, SR. World Health Organization, International Agency for Research on Cancer. Pathology and Genetics of tumours of the digestive system. Lyon; Oxford.: IARC press; Oxford University Press Distributor 2000.
6.
Schmitt AM, Blank A, Marinoni I, et al. Histopathology of NET: current concepts and new developments. Best Pract Res Clin Endocrinol Metab. 2016;30:33–43.PubMedCrossRef
7.
Adsay V. Ki67 labeling index in neuroendocrine tumors of the gastrointestinal and pancreatobiliary tract: to count or not to count is not the question, but rather how to count. Am J Surg Pathol. 2012;36:1743–6.PubMedCrossRef
8.
Schmitt AM, Anlauf M, Rousson V, et al. WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. Am J Surg Pathol. 2007;31:1677–82.PubMedCrossRef
9.
Bosman F, Carneiro F, Hruban RH, Theise ND. WHO classification of Tumours of the digestive system (4th edition). Lyon: IARC Press; 2010.
10.
Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395–401.PubMedPubMedCentralCrossRef
11.
Rindi G, Kloppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007;451:757–62.PubMedCrossRef
12.
Davis KP, Hartmann LK, Keeney GL, Shapiro H. Primary ovarian carcinoid tumors. Gynecol Oncol. 1996;61:259–65.PubMedCrossRef
13.
Robboy SJ, Norris HJ, Scully RE. Insular carcinoid primary in the ovary. A clinicopathologic analysis of 48 cases. Cancer. 1975;36:404–18.PubMedCrossRef
14.
Robboy SJ, Scully RE, Norris HJ. Primary trabecular carcinoid of the ovary. Obstet Gynecol. 1977;49:202–7.PubMed
15.
16.
Robboy SJ, Scully RE. Strumal carcinoid of the ovary: an analysis of 50 cases of a distinctive tumor composed of thyroid tissue and carcinoid. Cancer. 1980;46:2019–34.PubMedCrossRef
17.
Baker PM, Oliva E, Young RH, Talerman A, Scully RE. Ovarian mucinous carcinoids including some with a carcinomatous component: a report of 17 cases. Am J Surg Pathol. 2001;25:557–68.PubMedCrossRef
18.
Rabban JT, Lerwill MF, McCluggage WG, Grenert JP, Zaloudek CJ. Primary ovarian carcinoid tumors may express CDX-2: a potential pitfall in distinction from metastatic intestinal carcinoid tumors involving the ovary. Int J Gynecol Pathol. 2009;28:41–8.PubMedCrossRef
19.
Robboy SJ, Scully RE, Norris HJ. Carcinoid metastatic to the ovary. A clinicopathologic analysis of 35 cases. Cancer. 1974;33:798–811.PubMedCrossRef
20.
Eichhorn JH, Young RH, Scully RE. Primary ovarian small cell carcinoma of pulmonary type. A clinicopathologic, immunohistologic, and flow cytometric analysis of 11 cases. Am J Surg Pathol. 1992;16:926–38.PubMedCrossRef
21.
Veras E, Deavers MT, Silva EG, Malpica A. Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases. Am J Surg Pathol. 2007;31:774–82.PubMedCrossRef
22.
Lim SC, Choi JJ, Suh CH. A case of small cell carcinoma arising in mature cystic teratoma of the ovary. Pathol Int. 1998;48:834–9.PubMedCrossRef
23.
Rubio A, Schuldt M, Chamorro C, Crespo-Lora V, Nogales FF. Ovarian small cell carcinoma of pulmonary type arising in mature cystic Teratomas with metastases to the contralateral ovary. Int J Surg Pathol. 2015;23:388–92.PubMedCrossRef
24.
Ikota H, Kaneko K, Takahashi S, et al. Malignant transformation of ovarian mature cystic teratoma with a predominant pulmonary type small cell carcinoma component. Pathol Int. 2012;62:276–80.PubMedCrossRef
25.
McCluggage WG. Ovarian neoplasms composed of small round cells:a review. Adv Anat Pathol. 2004;11:288–96.PubMedCrossRef
26.
Witkowski L, Goudie C, Foulkes WD, McCluggage WG. Small-cell carcinoma of the ovary of hypercalcemic type (malignant rhabdoid tumor of the ovary): a review with recent developments on pathogenesis. Surg Pathol Clin. 2016;9:215–26.PubMedCrossRef
27.
McCluggage WG, Young RH. Paraganglioma of the ovary: report of three cases of a rare ovarian neoplasm, including two exhibiting inhibin positivity. Am J Surg Pathol. 2006;30:600–5.PubMedCrossRef
28.
Gonzalez-Bosquet E, Gonzalez-Bosquet J, et al. Carcinoid tumor of the uterine corpus. A case report. J Reprod Med. 1998;43:844–6.PubMed
29.
Chetty R, Clark SP, Bhathal PS. Carcinoid tumour of the uterine corpus. Virchows Arch A Pathol Anat Histopathol. 1993;422:93–5.PubMedCrossRef
30.
31.
Albores-Saavedra J, Martinez-Benitez B, Luevano E. Small cell carcinomas and large cell neuroendocrine carcinomas of the endometrium and cervix: polypoid tumors and those arising in polyps may have a favorable prognosis. Int J Gynecol Pathol. 2008;27:333–9.PubMedCrossRef
32.
Bahig H, Portelance L, Legler C, et al. Small cell carcinoma of the endometrium: report of a case and review of the literature. Minerva Ginecol. 2009;61:365–9.PubMed
33.
Bige O, Saatli B, Secil M, et al. Small cell neuroendocrine carcinoma of the endometrium and laparoscopic staging: a clinicopathologic study of a case and a brief review of the literature. Int J Gynecol Cancer. 2008;18:838–43.PubMedCrossRef
34.
Brudie LA, Khan F, Radi MJ, et al. Serous carcinoma of endometrium in combination with neuroendocrine small-cell: a case report and literature review. Gynecol Oncol Rep. 2016;17:79–82.PubMedPubMedCentralCrossRef
35.
Campo E, Brunier MN, Merino MJ. Small cell carcinoma of the endometrium with associated ocular paraneoplastic syndrome. Cancer. 1992;69:2283–8.PubMedCrossRef
36.
Chougule A, Garg R, Jain V. Paranuclear dot-like pancytokeratin positivity and MLH1/PMS2 loss in large cell neuroendocrine carcinoma of the endometrium. Pathology. 2016;48:736–9.PubMedCrossRef
37.
Chuang J, Chu CC, Hwang JL, et al. Small cell carcinoma of the endometrium with concomitant pelvic inflammatory disease. Arch Gynecol Obstet. 2002;266:178–80.PubMedCrossRef
38.
D'Antonio A, Addesso M, Caleo A, et al. Small cell neuroendocrine carcinoma of the endometrium with pulmonary metastasis: a clinicopathologic study of a case and a brief review of the literature. Ann Med Surg (Lond). 2016;5:114–7.CrossRef
39.
Deodhar KK, Kerkar RA, Suryawanshi P, et al. Large cell neuroendocrine carcinoma of the endometrium: an extremely uncommon diagnosis, but worth the efforts. J Cancer Res Ther. 2011;7:211–3.PubMedCrossRef
40.
Estruch A, Minig L, Illueca C, et al. Small cell neuroendocrine tumour of the endometrium and the importance of pathologic diagnosis. Ecancermedicalscience. 2016;10:668.PubMedPubMedCentralCrossRef
41.
Hunter RW, Williams KE, Buck M, et al. Metastatic small cell carcinoma of the endometrium: prolonged remission and possible cure following chemotherapy. Int J Gynecol Cancer. 1994;4:127–30.PubMedCrossRef
42.
Huntsman DG, Clement PB, Gilks CB, et al. Small-cell carcinoma of the endometrium. A clinicopathological study of sixteen cases. Am J Surg Pathol. 1994;18:364–75.PubMedCrossRef
43.
Hwang JH, Lee JK, Lee NW, et al. Primary small cell carcinoma of the endometrium: report of a case with immunochemical studies. J Reprod Med. 2010;55:81–6.PubMed
44.
Katahira A, Akahira J, Niikura H, et al. Small cell carcinoma of the endometrium: report of three cases and literature review. Int J Gynecol Cancer. 2004;14:1018–23.PubMedCrossRef
45.
Koo YJ, Kim DY, Kim KR, et al. Small cell neuroendocrine carcinoma of the endometrium: a clinicopathologic study of six cases. Taiwan J Obstet Gynecol. 2014;53:355–9.PubMedCrossRef
46.
Korcum AF, Aksu G, Ozdogan M, et al. Stage I small cell carcinoma of the endometrium: survival and management options. Acta Obstet Gynecol Scand. 2008;87:122–6.PubMedCrossRef
47.
Kumar NB. Small cell carcinoma of the endometrium in a 23-year-old woman: light microscopic and ultrastructural study. Am J Clin Pathol. 1984;81:98–101.PubMedCrossRef
48.
Makihara N, Maeda T, Nishimura M, et al. Large cell neuroendocrine carcinoma originating from the uterine endometrium: a report on magnetic resonance features of 2 cases with very rare and aggressive tumor. Rare Tumors. 2012;4:e37.PubMedPubMedCentralCrossRef
49.
Matsumoto H, Nasu K, Kai K, et al. Combined large-cell neuroendocrine carcinoma and endometrioid adenocarcinoma of the endometrium: a case report and survey of related literature. J Obstet Gynaecol Res. 2016;42:206–10.PubMedCrossRef
50.
Matsumoto H, Takai N, Nasu K, et al. Small cell carcinoma of the endometrium: a report of two cases. J Obstet Gynaecol Res. 2011;37:1739–43.PubMedCrossRef
51.
Meirmanov S, Nakashima M, Rogounovitch T, et al. Small cell carcinoma of the endometrium: report of a case with analysis of Wnt/beta-catenin pathway. Pathol Res Pract. 2003;199:551–8.PubMedCrossRef
52.
Melgoza F, Brewster WR, Wilczynski S, et al. p16-positive small cell neuroendocrine carcinoma of the endometrium. Int J Gynecol Pathol. 2006;25:252–6.PubMedCrossRef
53.
Meydanli MM, Erguvan R, Altinok MT, et al. Rare case of neuroendocrine small cell carcinoma of the endometrium with paraneoplastic membranous glomerulonephritis. Tumori. 2003;89:213–7.PubMed
54.
Mulvany NJ, Allen DG. Combined large cell neuroendocrine and endometrioid carcinoma of the endometrium. Int J Gynecol Pathol. 2008;27:49–57.PubMedCrossRef
55.
Nguyen ML, Han L, Minors AM, et al. Rare large cell neuroendocrine tumor of the endometrium: a case report and review of the literature. Int J Surg Case Rep. 2013;4:651–5.PubMedPubMedCentralCrossRef
56.
Olson N, Twiggs L, Sibley R. Small-cell carcinoma of the endometrium: light microscopic and ultrastructural study of a case. Cancer. 1982;50:760–5.PubMedCrossRef
57.
Paz RA, Frigerio B, Sundblad AS, et al. Small-cell (oat cell) carcinoma of the endometrium. Arch Pathol Lab Med. 1985;109:270–2.PubMed
58.
• Pocrnich CE, Ramalingam P, Euscher ED, et al. Neuroendocrine carcinoma of the endometrium: a clinicopathologic study of 25 cases. Am J Surg Pathol 2016; 40: 577–586. This is the largest published series of neuroendocrine carcinomas of the endometrium and stresses that these neoplasms are often misdiagnosed. 28% of patients survived greater than 5 years, a better survival than in other series.
59.
Posligua L, Malpica A, Liu J, et al. Combined large cell neuroendocrine carcinoma and papillary serous carcinoma of the endometrium with pagetoid spread. Arch Pathol Lab Med. 2008;132:1821–4.PubMed
60.
Proca D, Keyhani-Rofagha S, Copeland LJ, et al. Exfoliative cytology of neuroendocrine small cell carcinoma of the endometrium. A report of two cases. Acta Cytol. 1998;42:978–82.PubMedCrossRef
61.
Rajab KE, Sandhu AK, Malik A, et al. Small cell neuroendocrine carcinoma of the endometrium, a rare aggressive tumor. Saudi Med J. 2005;26:1130–2.PubMed
62.
Sato H, Kanai G, Kajiwara H, et al. Small-cell carcinoma of the endometrium presenting as Cushing's syndrome. Endocr J. 2010;57:31–8.PubMedCrossRef
63.
Sekiguchi I, Suzuki M, Sato I, et al. Rare case of small-cell carcinoma arising from the endometrium with paraneoplastic retinopathy. Gynecol Oncol. 1998;71:454–7.PubMedCrossRef
64.
Stachs A, Makovitzky J, Briese V. Small cell carcinoma of the endometrium: light microscopic and immunohistochemical study of a case. Anticancer Res. 2005;25:1823–5.PubMed
65.
Terada T. Large cell neuroendocrine carcinoma with sarcomatous changes of the endometrium: a case report with immunohistochemical studies and molecular genetic study of KIT and PDGFRA. Pathol Res Pract. 2010;206:420–5.PubMedCrossRef
66.
Terada T. KIT-positive primary small cell carcinoma of the endometrium: a case report with immunohistochemical and molecular genetic analysis of KIT and PDGFRA genes. Arch Gynecol Obstet. 2010;282:413–6.PubMedCrossRef
67.
Tohya T, Miyazaki K, Katabuchi H, et al. Small cell carcinoma of the endometrium associated with adenosquamous carcinoma: a light and electron microscopic study. Gynecol Oncol. 1986;25:363–71.PubMedCrossRef
68.
Tsujioka H, Eguchi F, Emoto M, et al. Small-cell carcinoma of the endometrium: an immunohistochemical and ultrastructural analysis. J Obstet Gynaecol Res. 1997;23:9–16.PubMedCrossRef
69.
70.
van Hoeven KH, Hudock JA, Woodruff JM, et al. Small cell neuroendocrine carcinoma of the endometrium. Int J Gynecol Pathol. 1995;14:21–9.PubMedCrossRef
71.
Varras M, Akrivis C, Demou A, et al. Primary small-cell carcinoma of the endometrium: clinicopathological study of a case and review of the literature. Eur J Gynaecol Oncol. 2002;23:577–81.PubMed
72.
Atienza-Amores M, Guerini-Rocco E, Soslow RA, et al. Small cell carcinoma of the gynecologic tract: a multifaceted spectrum of lesions. Gynecol Oncol. 2014;134:410–8.PubMedCrossRef
73.
Taraif SH, Deavers MT, Malpica A, et al. The significance of neuroendocrine expression in undifferentiated carcinoma of the endometrium. Int J Gynecol Pathol. 2009;28:142–7.PubMedCrossRef
74.
Gilks CB, Young RH, Gersell DJ, Clement PB. Large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic study of 12 cases. Am J Surg Pathol. 1997;21:905–14.PubMedCrossRef
75.
Sato Y, Shimamoto T, Amada S, et al. Large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathological study of six cases. Int J Gynecol Pathol. 2003;22:226–30.PubMedCrossRef
76.
Conner MG, Richter H, Moran CA, et al. Small cell carcinoma of the cervix: a clinicopathologic and immunohistochemical study of 23 cases. Ann Diagn Pathol. 2002;6:345–8.PubMedCrossRef
77.
Grayson W, Rhemtula HA, Taylor LF, et al. Detection of human papillomavirus in large cell neuroendocrine carcinoma of the uterine cervix: a study of 12 cases. J Clin Pathol. 2002;55:108–14.PubMedPubMedCentralCrossRef
78.
Ishida GM, Kato N, Hayasaka T, et al. Small cell neuroendocrine carcinomas of the uterine cervix: a histological, immunohistochemical and molecular genetic study. Int J Gynecol Pathol. 2004;23:366–72.PubMedCrossRef
79.
Stoler MH, Mills SE, Gersell DJ, Walker AN. Small-cell neuroendocrine carcinoma of the cervix. A human papillomavirus type 18-associated cancer. Am J Surg Pathol. 1991;15:28–32.PubMedCrossRef
80.
McCluggage WG, Kennedy K, Busam KJ. An immunohistochemical study of cervical neuroendocrine carcinomas: neoplasms that are commonly TTF1 positive and which may express CK20 and P63. Am J Surg Pathol. 2010;34:525–32.PubMedCrossRef
81.
• Ganesan R, Hirschowitz L, Dawson P, et al. Neuroendocrine carcinoma of the cervix: review of a series of cases and correlation with outcome. Int J Surg Pathol 2016;24:490–496. This is one of the largest reported series of cervical neuroendocrine carcinomas. In this study, central pathology review was undertaken and this confirmed significantly reduced survival in those patients with confirmed neuroendocrine carcinoma in comparison with those patients where a diagnosis of neuroendocrine carcinoma was not confirmed.
82.
Houghton O, McCluggage WG. The expression and diagnostic utility of p63 in the female genital tract. Adv Anat Pathol. 2009;16:316–21.PubMedCrossRef
83.
Sheikh ZA, Nair I, Vijaykumar DK, et al. Neuroendocrine tumor of vulva: a case report and review of literature. J Cancer Res Ther. 2010;6:365–6.PubMedCrossRef
84.
Pawar R, Vijayalakshmy AR, Khan S, et al. Primary neuroendocrine carcinoma (Merkel's cell carcinoma) of the vulva mimicking as a Bartholin's gland abscess. Ann Saudi Med. 2005;25:161–4.PubMed
85.
Nuciforo PG, Fraggetta F, Fasani R, et al. Neuroendocrine carcinoma of the vulva with paraganglioma-like features. Histopathology. 2004;44:304–6.PubMedCrossRef
86.
Hierro I, Blanes A, Matilla A, et al. Merkel cell (neuroendocrine) carcinoma of the vulva. A case report with immunohistochemical and ultrastructural findings and review of the literature. Pathol Res Pract. 2000;196:503–9.PubMedCrossRef
87.
Fawzi HW, Cross PA, Buckley CH, et al. Neuroendocrine (Merkel cell) carcinoma of the vulva. J Obstet Gynaecol. 1997;17:100–1.PubMedCrossRef
88.
89.
Husseinzadeh N, Wesseler T, Newman N, et al. Neuroendocrine (Merkel cell) carcinoma of the vulva. Gynecol Oncol. 1988;29:105–12.PubMedCrossRef
90.
Copeland LJ, Cleary K, Sneige N, et al. Neuroendocrine (Merkel cell) carcinoma of the vulva: a case report and review of the literature. Gynecol Oncol. 1985;22:367–78.PubMedCrossRef
91.
Matsumoto R, Bito T, Washio K, et al. Primary cutaneous small cell carcinoma of the vulva arising from squamous cell carcinoma. Br J Dermatol. 2011;165:1147–8.PubMedCrossRef
92.
Bing Z, Levine L, Lucci JA, et al. Primary small cell neuroendocrine carcinoma of the vagina: a clinicopathologic study. Arch Pathol Lab Med. 2004;128:857–62.PubMed
93.
Colleran KM, Burge MR, Crooks LA, et al. Small cell carcinoma of the vagina causing Cushing's syndrome by ectopic production and secretion of ACTH: a case report. Gynecol Oncol. 1997;65:526–9.PubMedCrossRef
94.
Petru E, Pasterk C, Reich O, et al. Small-cell carcinoma of the uterus and the vagina: experience with ten patients. Arch Gynecol Obstet. 2005;271:316–9.PubMedCrossRef
95.
Oliveira R, Bocoli MC, Saldanha JC, et al. Primary small cell carcinoma of the vagina. Case Rep Obstet Gynecol. 2013;2013:827037.PubMedPubMedCentral
96.
Koo J, Dhall D. Problems with the diagnosis of metastatic neuroendocrine neoplasms. Which diagnostic criteria should we use to determine tumor origin and help guide therapy? Semin Diagn Pathol. 2015;32(6):456–68.PubMedCrossRef
97.
Plockinger U, Wiedenmann B. Treatment of gastroenteropancreatic neuroendocrine tumors. Virchows Arch. 2007;451(Suppl 1):S71–80.PubMedCrossRef
98.
Pavel M, O'Toole D, Costa F, et al. ENETS consensus guidelines update for the Management of Distant Metastatic Disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103(2):172–85.PubMedCrossRef
99.
Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010;28(1):69–76.PubMedCrossRef
100.
Lin X, Saad RS, Luckasevic TM, et al. Diagnostic value of CDX-2 and TTF-1 expressions in separating metastatic neuroendocrine neoplasms of unknown origin. Appl Immunohistochem Mol Morphol. 2007;15(4):407–14.PubMedCrossRef
101.
Srivastava A, Hornick JL. Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors. Am J Surg Pathol. 2009;33(4):626–32.PubMedCrossRef
102.
Weissferdt A, Tang X, Wistuba II, et al. Comparative immunohistochemical analysis of pulmonary and thymic neuroendocrine carcinomas using PAX8 and TTF-1. Mod Pathol. 2013;26(12):1554–60.PubMedCrossRef
103.
Chan ES, Alexander J, Swanson PE, et al. PDX-1, CDX-2, TTF-1, and CK7: a reliable immunohistochemical panel for pancreatic neuroendocrine neoplasms. Am J Surg Pathol. 2012;36(5):737–43.PubMedCrossRef
104.
Koo J, Zhou X, Moschiano E, et al. The immunohistochemical expression of islet 1 and PAX8 by rectal neuroendocrine tumors should be taken into account in the differential diagnosis of metastatic neuroendocrine tumors of unknown primary origin. Endocr Pathol. 2013;24(4):184–90.PubMedCrossRef
105.
La Rosa S, Chiaravalli AM, Placidi C, et al. TTF1 expression in normal lung neuroendocrine cells and related tumors: immunohistochemical study comparing two different monoclonal antibodies. Virchows Arch. 2010;457(4):497–507.PubMedCrossRef
106.
Bellizzi AM. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnostic immunohistochemistry. Adv Anat Pathol. 2013;20(5):285–314.PubMedCrossRef
107.
Barbareschi M, Roldo C, Zamboni G, et al. CDX-2 homeobox gene product expression in neuroendocrine tumors: its role as a marker of intestinal neuroendocrine tumors. Am J Surg Pathol. 2004;28(9):1169–76.PubMedCrossRef
108.
Denby KS, Briones AJ, Bourne PA, et al. IMP3, NESP55, TTF-1 and CDX2 serve as an immunohistochemical panel in the distinction among small-cell carcinoma, gastrointestinal carcinoid, and pancreatic endocrine tumor metastasized to the liver. Appl Immunohistochem Mol Morphol. 2012;20(6):573–9.PubMedCrossRef
109.
Erickson LA, Papouchado B, Dimashkieh H, et al. Cdx2 as a marker for neuroendocrine tumors of unknown primary sites. Endocr Pathol. 2004;15(3):247–52.PubMedCrossRef
110.
Graham RP, Shrestha B, Caron BL, et al. Islet-1 is a sensitive but not entirely specific marker for pancreatic neuroendocrine neoplasms and their metastases. Am J Surg Pathol. 2013;37(3):399–405.PubMedCrossRef
111.
La Rosa S, Rigoli E, Uccella S, et al. CDX2 as a marker of intestinal EC-cells and related well-differentiated endocrine tumors. Virchows Arch. 2004;445(3):248–54.PubMedCrossRef
112.
Haynes CM, Sangoi AR, Pai RK. PAX8 is expressed in pancreatic well-differentiated neuroendocrine tumors and in extrapancreatic poorly differentiated neuroendocrine carcinomas in fine-needle aspiration biopsy specimens. Cancer Cytopathol. 2011;119(3):193–201.PubMedCrossRef
113.
Koo J, Mertens RB, Mirocha JM, et al. Value of islet 1 and PAX8 in identifying metastatic neuroendocrine tumors of pancreatic origin. Mod Pathol. 2012;25(6):893–901.PubMedCrossRef
114.
Long KB, Srivastava A, Hirsch MS, et al. PAX8 expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors. Am J Surg Pathol. 2010;34(5):723–9.PubMed
115.
Lorenzo PI, Jimenez Moreno CM, Delgado I, et al. Immunohistochemical assessment of Pax8 expression during pancreatic islet development and in human neuroendocrine tumors. Histochem Cell Biol. 2011;136(5):595–607.PubMedPubMedCentralCrossRef
116.
Ozcan A, Liles N, Coffey D, et al. PAX2 and PAX8 expression in primary and metastatic mullerian epithelial tumors: a comprehensive comparison. Am J Surg Pathol. 2011;35(12):1837–47.PubMedCrossRef
117.
Sangoi AR, Ohgami RS, Pai RK, et al. PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma. Mod Pathol. 2011;24(3):412–24.PubMedCrossRef
118.
Moreno CM, Lorenzo PI, Delgado I, et al. Pax8 detection in well-differentiated pancreatic endocrine tumors: how reliable is it? Am J Surg Pathol. 2011;35(12):1906–8.PubMedCrossRef
119.
Agaimy A, Erlenbach-Wunsch K, Konukiewitz B, et al. ISL1 expression is not restricted to pancreatic well-differentiated neuroendocrine neoplasms, but is also commonly found in well and poorly differentiated neuroendocrine neoplasms of extrapancreatic origin. Mod Pathol. 2013;26(7):995–1003.PubMedCrossRef
120.
Hermann G, Konukiewitz B, Schmitt A, et al. Hormonally defined pancreatic and duodenal neuroendocrine tumors differ in their transcription factor signatures: expression of ISL1, PDX1, NGN3, and CDX2. Virchows Arch. 2011;459(2):147–54.PubMedCrossRef
121.
Schmitt AM, Riniker F, Anlauf M, et al. Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases. Am J Surg Pathol. 2008;32(3):420–5.PubMedCrossRef
122.
Tseng IC, Yeh MM, Yang CY, et al. NKX6-1 is a novel Immunohistochemical marker for pancreatic and duodenal neuroendocrine tumors. Am J Surg Pathol. 2015;39(6):850–7.PubMedCrossRef
123.
Federspiel BH, Burke AP, Sobin LH, et al. Rectal and colonic carcinoids. A clinicopathologic study of 84 cases. Cancer. 1990;65(1):135–40.PubMedCrossRef
124.
Kimura N, Sasano N. Prostate-specific acid phosphatase in carcinoid tumors. Virchows Arch A Pathol Anat Histopathol. 1986;410(3):247–51.PubMedCrossRef
125.
• Alos L, Hakim S, Larque AB, et al. p16 overexpression in high-grade neuroendocrine carcinomas of the head and neck: potential diagnostic pitfall with HPV-related carcinomas. Virchows Arch 2016;469;277–284. This paper shows that non-HPV related neuroendocrine carcinomas of the head and neck may be diffusely positive with p16 illustrating that this marker is of no value in confirming a uterine cervical primary for a disseminated neuroendocrine carcinoma.
Metadata
Title
Pathology of Neuroendocrine Tumours of the Female Genital Tract
Authors
Brooke E. Howitt
Paul Kelly
W. Glenn McCluggage
Publication date
01-09-2017
Publisher
Springer US
Published in
Current Oncology Reports / Issue 9/2017
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-017-0617-2

Other articles of this Issue 9/2017

Current Oncology Reports 9/2017 Go to the issue

Lymphomas (MR Smith, Section Editor)

Targeting B Cell Signaling in Chronic Lymphocytic Leukemia

Head and Neck Cancers (EY Hanna, Section Editor)

Surgical Management of Periocular Cancers: High- and Low-Risk Features Drive Treatment

Neuro-oncology (S Nagpal, Section Editor)

New Hypofractionation Radiation Strategies for Glioblastoma

Geriatric Oncology (AR MacKenzie, Section Editor)

Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults

Integrative Care (C Lammersfeld, Section Editor)

Mindfulness-Based Interventions and Sleep Among Cancer Survivors: a Critical Analysis of Randomized Controlled Trials
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits